Literature DB >> 29799952

Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis.

Mathieu Jouvray1,2,3,4, David Launay1,2,3,4, Sylvain Dubucquoi1,2,5, Vincent Sobanski1,2,3,4, Céline Podevin1,2,4, Marc Lambert1,2,3,4, Sandrine Morell-Dubois3,4, Hélène Maillard3,4, Pierre-Yves Hatron3,4, Eric Hachulla1,2,3,4, Jonathan Giovannelli1,2,3,4.   

Abstract

Importance: In systemic sclerosis (SSc), to date, no study has precisely described the total number and fine distribution of telangiectases (TAs), their clinical association with the disease, and the biological mechanisms causing their development.
Objectives: To describe the whole-body distribution of TAs and assess the association between the whole-body TA number and the characteristics of patients with SSc. Design, Setting, and Participants: A single-center, cross-sectional study was conducted between July 11, 2016, and March 15, 2017, at the National Referral Centre for Rare Systemic and Autoimmune Diseases in France. A population-based sample of 106 adults who fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc were included; 8 patients who had previously received laser treatment for TAs were excluded. Main Outcomes and Measures: The number of TAs on the whole body (total and those >5 mm) and TA distribution in different areas were recorded. The association with clinical and biological data was studied using univariate and multivariate linear regression.
Results: A total of 106 patients (83 [78.3%] women) were enrolled, including 12 with precapillary pulmonary hypertension (PH). Mean (SD) age was 60.6 (13.5) years. Telangiectasia distribution was 37.2% on the face, 33.2% on the upper limbs, including 26.4% on the hands, 28.1% on the trunk, including 17.1% for the upper part of the trunk, and 1.5% on the lower limbs. In analysis using the multivariate linear regression model, the whole-body TA number was independently associated with male sex (percentage change, 144.4%; 95% CI, 7.5% to 455.9%; P = .03), PH (162.8%; 95% CI, 5.6% to 553.8%; P = .04), history of pulmonary embolism (336.4%; 95% CI, 39.0% to 1270.1%; P = .01), glomerular filtration rate (-1.6%; 95% CI, -3.2% to -0.1% per 1-mL/min/1.73 m2 increase; P = .04), and soluble endoglin level (28.2%; 95% CI, 1.2% to 62.5% per 1-ng/mL increase; P = .04). Receiver operating characteristic analyses assessing the ability of TAs to identify the presence of PH revealed that the area under the curve was significant for the TA number on the whole body (0.77; 95% CI, 0.57 to 0.88), on the hands and face (0.81; 95% CI, 0.57 to 0.91), and on the hands (95% CI, 0.77; 95% CI, 0.57 to 0.89). Conclusions and Relevance: In the patients in this study with SSc, TAs were predominantly located on the face, hands, and the upper part of the trunk. Telangiectases appeared to be associated with vasculopathy features of SSc, particularly with PH and soluble endoglin levels.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29799952      PMCID: PMC6128493          DOI: 10.1001/jamadermatol.2018.0916

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  39 in total

Review 1.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

3.  Pathogenesis of telangiectasia in scleroderma.

Authors:  T L Mould; P J Roberts-Thomson
Journal:  Asian Pac J Allergy Immunol       Date:  2000-12       Impact factor: 2.310

4.  Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease.

Authors:  Charlotte Hurabielle; Jérôme Avouac; Gemma Lepri; Tullia de Risi; André Kahan; Yannick Allanore
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-07       Impact factor: 4.794

5.  Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis.

Authors:  Carmen Pizzorni; Anna R Giampetruzzi; Chiara Mondino; Antonio Facchiano; Damiano Abeni; Sabrina Paolino; Barbara Ruaro; Vanessa Smith; Alberto Sulli; Maurizio Cutolo
Journal:  Microvasc Res       Date:  2016-12-16       Impact factor: 3.514

6.  Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.

Authors:  Claire L Shovlin; N Laila Sulaiman; Fatima S Govani; James E Jackson; Megan E Begbie
Journal:  Thromb Haemost       Date:  2007-11       Impact factor: 5.249

7.  Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study.

Authors:  Sreeram V Ramagopalan; Clare J Wotton; Adam E Handel; David Yeates; Michael J Goldacre
Journal:  BMC Med       Date:  2011-01-10       Impact factor: 8.775

8.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.

Authors:  Oliver Distler; Angela Del Rosso; Roberto Giacomelli; Paola Cipriani; Maria L Conforti; Serena Guiducci; Renate E Gay; Beat A Michel; Pius Brühlmann; Ulf Müller-Ladner; Steffen Gay; Marco Matucci-Cerinic
Journal:  Arthritis Res       Date:  2002-08-30

Review 9.  VEGF-A splicing: the key to anti-angiogenic therapeutics?

Authors:  Steven J Harper; David O Bates
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

10.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Authors:  J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Oliver Distler; Dinesh Khanna; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; Martin Doelberg; Harbajan Chadha-Boreham; Harald Heinzl; Daniel M Rosenberg; Vallerie V McLaughlin; James R Seibold
Journal:  Ann Rheum Dis       Date:  2013-05-18       Impact factor: 19.103

View more
  3 in total

Review 1.  Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.

Authors:  Anna Kowalska-Kępczyńska
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

2.  Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.

Authors:  M R Pokeerbux; J Giovannelli; L Dauchet; L Mouthon; C Agard; J C Lega; Y Allanore; P Jego; B Bienvenu; S Berthier; A Mekinian; E Hachulla; D Launay
Journal:  Arthritis Res Ther       Date:  2019-04-03       Impact factor: 5.156

3.  Endoglin and Systemic Sclerosis: A PRISMA-driven systematic review.

Authors:  Silvia Grignaschi; Anna Sbalchiero; Giuseppe Spinozzi; Bianca Lucia Palermo; Claudia Cantarini; Chantal Nardiello; Lorenzo Cavagna; Carla Olivieri
Journal:  Front Med (Lausanne)       Date:  2022-08-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.